Changes in excitability and ion channel expression in neurons of the major pelvic ganglion in female type II diabetic mice

Michael Gray^{1*}, Kawasi M. Lett^{1*}, Virginia B. Garcia¹, Cindy W. Kyi¹, Kathleen A. Pennington², Laura C. Schulz², David J. Schulz¹

¹ *Division of Biological Sciences, University of Missouri, Columbia, MO USA 65211*

² *Department of Obstetrics, Gynecology and Women's Health, University of Missouri, Columbia, MO, 65211, USA.*

** Denotes equal contribution by these authors*

Abbreviated Title

Changes in parasympathetic neurons in Type II diabetes

Corresponding Author

David J. Schulz, Ph.D.
Division of Biological Sciences
University of Missouri-Columbia
218 LeFevre Hall
Columbia, MO 65211
Ph 573-882-4067
Fax 573-884-5020
Email: schulzd@missouri.edu

Acknowledgments

This work was funded by a grant from the Missouri Spinal Cord Injuries Research Program (D.J.S.), the Craig H. Neilsen Foundation (D.J.S.), American Diabetes Association Grant 1-14-BS-181 (L.C.S.) and American Heart Association Postdoctoral Fellowship 13POST16910108 (K.A.P.). The authors declare no competing financial interests.

ABSTRACT

Bladder cystopathy is a common urological complication of diabetes, and has been associated with changes in parasympathetic ganglionic transmission and some measures of neuronal excitability in male mice. To determine whether type II diabetes also impacts excitability of parasympathetic ganglionic neurons in females, we investigated neuronal excitability and firing properties, as well as underlying ion channel expression, in major pelvic ganglion (MPG) neurons in control, 10-week, and 21-week db/db mice. Type II diabetes in *Lepr^{db/db}* animals caused a non-linear change in excitability and firing properties of MPG neurons. At 10 weeks, cells exhibited increased excitability as demonstrated by an increased likelihood of firing multiple spikes upon depolarization, decreased rebound spike latency, and overall narrower action potential half-widths as a result of increased depolarization and repolarization slopes. Conversely, at 21 weeks MPG neurons of db/db mice reversed these changes, with spiking patterns and action-potential properties largely returning to control levels. These changes are associated with numerous time-specific changes in calcium, sodium, and potassium channel subunit mRNA levels. However, Principal Components Analysis of channel expression patterns revealed that the rectification of excitability is not simply a return to control levels, but rather a distinct ion channel expression profile in 21-week db/db neurons. These data indicate that type II diabetes can impact the excitability of post-ganglionic, parasympathetic bladder-innervating neurons of female mice, and suggest that the non-linear progression of these properties with diabetes may be the result of compensatory changes in channel expression that act to rectify disrupted firing patterns of db/db MPG neurons.

Keywords: type II diabetes, diabetic cystopathy, autonomic ganglia, parasympathetic neurons, excitability, electrophysiology

INTRODUCTION

Diabetes is a systemic, progressive disease characterized by lack of insulin directly (Type I), or functional lack of its effectors and/or insulin resistance (Type II), that ultimately leads to hyperglycemia and chronic complications. Diabetes is the seventh leading cause of death in the United States and afflicts 11.1-11.9% of adults over the age of 20; this rate has increased from 8.9% in years 1988-1994 to 11.9 % in years 2011-2014 (United States. Department of Health and Human Services. et al. 2016). In addition, diabetic complications are age dependent (Gunnarsson 1975; DCCT Research Group 1996; Liu et al. 2017). This age dependence combined with the 111.5% increase in persons age 65 and older from 1975-2015 (United States. Department of Health and Human Services. et al. 2016), necessitates studying an important complication of diabetes—diabetic neuropathy.

Diabetic neuropathy is particularly dangerous due to its insidious development, susceptibility of autonomic neurons and their subsequent regulation of vital organ systems, and a potential for positive feedback loops through dysregulation of microvasculature (Faerman et al. 1971; Vinik et al. 2003). Interventions are difficult as symptoms are subclinical and are often undiagnosed until long after neural lesions occur. That is, autonomic motor neuron damage occurs long before patients report somatic sensory symptoms. This is supported by the finding that in diabetic mice, thin, non-myelinated post ganglionic autonomic motor neurons show deficits long before somatic sensory motoneurons do (Liu et al. 2017). Neuropathic lesions can affect various autonomic pathways resulting in gastroparesis (Vinik et al. 2003), cardiovascular dysregulation (Vinik et al. 2003, 2011), sudomotor dysfunction (Liu et al. 2017), diabetic cystopathy (Faerman et al. 1971; Frimodt-Moller 1980; Kaplan et al. 1995; Vinik et al. 2003), and dysregulation of blood flow in the periphery (UKPDS 1998). Bladder dysfunction as a result of diabetes (i.e. diabetic cystopathy) is characterized by reduced bladder sensation, increased post-residual void volume and overactive bladder (Kaplan et al. 1995; Yuan et al. 2015), and was first formally described in diabetics in 1864 (Faerman et al. 1971). Some of the effects of diabetic cystopathy can be attributed to damaged bladder afferents. For example, it has been shown in streptozocin (STZ) treated rats

(type I diabetes model) that diabetic cystopathy is correlated with reduced levels of nerve growth factor (NGF) in dorsal root ganglion neurons (Sasaki et al. 2002). Furthermore, when NGF is expressed at the bladder wall, the development of diabetic cystopathy and subsequent increased post residual void volume can be mitigated (Sasaki et al. 2004). However, little is known as to how diabetes impacts autonomic neurons innervating the bladder, and how this contributes to autonomic neuropathy and bladder cystopathy.

The major pelvic ganglion (MPG) of the mouse is the primary motor innervation of the urinary bladder. When examining motor neurons of this network in males, Tompkins et al. (2013), found that in post-ganglionic, parasympathetic, MPG neurons in *Lepr^{db/db}* mice had an enhanced number of excitatory post-synaptic potentials (EPSP) up to 20 seconds after pelvic nerve stimulation relative to control. Simultaneously, the authors observed no change in EPSP amplitude. However, STZ-treated mice did not differ in EPSP number and had significantly reduced amplitudes relative to control mice. This suggests that the type I and type II models are distinct in how they affect physiology of MPG neurons. Furthermore, change in action potential properties is similarly dependent on diabetic type: after-hyperpolarization (AHP) duration was significantly decreased in *Lepr^{db/db}* mice, while being significantly increased in STZ mice (Tompkins et al. 2013). Finally, MPG neuron input resistance and resting membrane potential are decreased and depolarized, respectively, in *Lepr^{db/db}* mice but unaffected in STZ mice (Tompkins et al. 2013). These results suggest that both EPSP and intrinsic properties of MPG neurons are differentially modulated by the nature of the diabetic model.

In this study, we exploit the *Lepr^{db/db}* C57BL/6J mouse, to extend our understanding of how type II diabetes affects progression of changes in neuronal excitability in neurons of the MPG of female mice. Specifically, we examine how these conditions change neurons at 10- and 21-week time points by combining current clamp recordings of neuronal output with ion channel expression analyses in the MPGs of female mice. We predicted that firing properties and intrinsic properties should resemble that observed by Tompkins et al. (2013); with a general increase in excitability at week 21 to evoked firing

rate, an increased RMP, decreased input resistance, and increased AHP duration. However, we observed a distinct effect: excitability of MPG neurons was initially increased at 10-weeks, but subsequently became less excitable again – towards baseline levels – at 21-weeks. These results suggest a compensatory change in MPG neurons in diabetic animals. We then went on to investigate potential underlying mechanisms for these changes via measurements of ion channel mRNA levels in MPGs from 10-week and 21-week diabetic females.

METHODS

Type II Diabetes Model – Lepr^{db/db} Animals

Wild type (WT) C57BL/6J and Lepr^{db/db} female mice (*Mus musculus*) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Lepr^{db/db} mice have a mutation that interrupts the longest isoform of the leptin receptor (Chen et al. 1996). These animals display hyperphagia, obesity, hyperglycemia and hyperinsulinemia, which has led to their widespread use as a model of type II diabetes. Together, mouse and rat leptin mutants have been used in over 4000 published studies of type II diabetes (Wang et al. 2014). Lepr^{db/db} mice have been used by the Animal Models of Diabetic Complications Consortium and others as models for diabetic neuropathy (Sullivan et al. 2007).

Mice were group housed in cages on a 12 hr. light/dark cycle and fed a standard chow diet ad libitum. All animal procedures were performed in accordance with National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the University of Missouri Animal Care and Use Committee.

Establishing a Diabetic Phenotype

Glucose Measurement. At either 10 (n = 15 WT and 14 Lepr^{db/db}) or 21 (n = 6 WT and 14 Lepr^{db/db}) weeks of age animals were fasted for 4 hours and then a fasting glucose measurement was taken via tail blood using the average of two readings of a OneTouch® (Sunnyvale, CA) or ReliOn Prime® (Arkay inc., Kyoto, Japan; Distributed by Walmart, Bentonville, AR) Blood Glucose Monitoring System. At this time blood was collected to measure fasting serum insulin levels. Weights were also recorded at this time.

Insulin Elisa. Serum insulin levels were analyzed using a Mouse/Rat Insulin Elisa (Millipore™, Billerica, MA) according to manufacturer's instructions. A total number of 6 samples at 10 weeks were run for both WT and Lepr^{db/db} females. At 21 weeks of age 9 Lepr^{db/db} and 6 WT females were analyzed. For Lepr^{db/db} serum was diluted at 1:20 with matrix solution provided in the ELSIA kit to allow for measurements to fall on the standard curve.

Electrophysiology

MPGs were dissected from isoflurane euthanized female mice from wildtypes (n = 9) at 10 weeks (WT), Lepr^{db/db} at 10 weeks (n = 5; DB10), or Lepr^{db/db} at 21 weeks (n = 5; DB21). Dissection and all experiments were done in oxygenated physiological saline at room temperature. MPGs were dissected out and pinned to a Sylgard (Dow, Midland, MI) lined perfusion chamber. The preparation was then desheathed using small pins to remove excess tissue. Saline was composed of in mM: NaCl, 146; KCl, 4.7; MgSO₄, 0.6; NaHCO₃, 1.6; NaH₂PO₄, 0.13; CaCl₂, 2.5; Glucose, 7.8; HEPES, 20; pH'd to 7.3. Electrodes were pulled on a P-97 microelectrode puller (Sutter, Novato, CA) filled with 3M KCl, and had resistances of 30 to 60 MΩ. Recordings were acquired in Bridge mode using an Axoclamp 900A and digitized using a Digidata 1440A using the pClamp 10.3 suite of software (Molecular Devices, Sunnyvale, Ca) running on an IBM-compatible computer. Silver electrode and ground wire were chlorided using household Bleach (Clorox, Oakland, CA).

Passive properties. Resistance, time constant, capacitance and rebound spikes were estimated from -500 pA current injections of 400 ms. In some protocols where there were no rebound spikes, these properties were estimated from -500 pA current injections for 2000 ms. To ensure these protocols did not differ, we examined action potential properties for 12 WT neurons where both protocols were used. A paired t-test showed that hyperpolarization duration did not significantly affect these measurements, the closest measurement to being affected was AHP ($t(11) = 2.090$, $p = 0.061$) while all other properties were unaffected ($p > 0.1$). Due to the contamination of slow activating currents and membranes being non-isopotential in real neurons, time was estimated by the 2 exponential fit; $V_m(t) = V_{final} + A_1 e^{-t/\tau_1} + A_2 e^{-t/\tau_2}$; the larger A (IR) and time constant term were taken to be the time constant (Golowasch et al. 2009; White and Hooper 2013). Capacitance was estimated from this time constant and input resistance. For excitability data, current was injected from 0 to 700 pA in 50 pA steps for 400 ms.

Action Potential Properties. Action potential properties were estimated both manually (Spike count, Rheobase, AP slope to depolarizing current injection, and Threshold) and by using the auto-statistics package of the Clampfit program from the pClamp 10.3 suite of software (Molecular Devices, Sunnyvale, Ca) (All others). These properties are illustrated in figure 1 for reference, and unless otherwise stated were performed on rebound spikes to prevent contamination from current injection.

Threshold measurement. Threshold was measured from two methods and verified by estimation from passive properties and rheobase. First, we extrapolated manually from step protocols. Second, we adopted an adapted version of the spike slope method, where the derivative of voltage with respect to time slope is plotted vs voltage and the voltage at which this slope meets or exceeds some slope is threshold usually set from 2 to 20 mV/ms (Naundorf et al. 2006; Platkiewicz and Brette 2010, 2011). However, rather than using constant ascending spike slope, this method was adapted by measuring maximal ascending slope within a 0.5 ms bin, defining threshold as the voltage recorded 0.25 ms before the center point of the half maximal bin. Within wildtype, no significant differences were found between this

method ($M = -23.5$, $SD = 8.1$) and manual estimation ($M = -23.5$, $SD = 8.1$). Slope method was chosen to minimize any confounds between changes in ascending slope.

Inclusion Criterion. Some neurons impaled produced no spikes. As we could not ascertain whether this was due to impalement damage, or these cells being silent neurons or closely apposed satellite glial cells (Hanani 2010), the following inclusion criteria were made: 1) All neurons must produce spikes to depolarizing current injections. 2) All cells must have resting membrane potentials less than -30 mV. 3) All cells must have input resistances greater than ~ 18 M Ω .

Statistics. Data was organized and stored in Microsoft Excel (Microsoft, Redmond, WA). All Statistics and graphs were made in Sigmaplot 11.0 (Chicago, IL), R (<https://www.r-project.org/>) and formatted in Adobe Illustrator CC 2017 (San Jose, CA). Data that passed normality testing and were shown to be homoscedastic were analyzed using one-way ANOVA. Most Data, however, was found to be non-normal and /or fail equal variance and comparisons were therefore made with a non-parametric Kruskal-Wallis one-way ANOVA on ranks using a post-hoc Dunn's test. The two-way ANOVA for Figure 3B failed the assumptions of normality and homoscedasticity and could not be successfully transformed, statistics are reported for raw data.

qRT-PCR Methods

Paired MPGs from each animal were collected into Trizol reagent (Life Technologies, Carlsbad, CA), homogenized, and stored at -80°C until RNA extraction. Total RNA was isolated from MPGs according to the protocol provided by the manufacturer. Complementary DNA (cDNA) was generated from 100 ng total RNA primed by a mixture of random hexamers and oligo-dT primers. Reverse transcription reactions were carried out at a volume of 20 μl using qScript cDNA SuperMix (QuantaBio, Beverly, MA) according to manufacturer protocols. Following cDNA synthesis, the reaction was heat inactivated and diluted 5X to a final volume of 100 μl before being used as a template for quantitative

PCR (qPCR). From each cDNA reaction we quantified at least 15 different gene products. Multiple cDNA synthesis reactions were carried out from a single total RNA sample to quantify the full suite of genes examined in this study.

In our previous work, we designed or modified and independently validated qPCR primers for use in absolute quantitation of mRNA copy number for all of the genes of interest in this study. These primer sets are previously published, and standard curves generated and used as described in our previous work (Garcia et al. 2014, 2018). Briefly, qPCR reactions were carried out using SYBR mastermix (BioRad) according to the manufacturer's instructions, and consisted of primers at final concentrations of 2.5 μ M. Reactions were carried out on a CFXConnect (BioRad) machine with a three-step cycle of 95°C-15s, 58°C-20s, 72°C-20s, followed by a melt curve from 65°C to 95°C. Fluorescence data acquisition was made at the 72°C step, and every 0.5°C of the melt curve. All reactions were run in triplicate, and the average Ct (cycle threshold) was used for interpolation with standard curves to generate copy number for a given reaction.

The unit we use to express all of the qPCR data in this study is “copy number per ng of total RNA,” and reflects the amount of input RNA that went into the cDNA synthesis reaction. All of the data were normalized (see Garcia et al. 2014) relative to the average expression of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), beta-actin, and hypoxanthine guanine phosphoribosyl transferase (HPRT) genes from each sample (Vandesompele et al. 2002). Samples that were found to have low expression of these control genes were eliminated from the analysis. None of the control genes showed significant differences in expression across groups.

RESULTS

Lepr^{db/db} mice produce a diabetic phenotype with hyperglycemia that differs according to age. Diabetic neuropathy and the metabolic derangements of diabetes itself (Gunnarsson 1975; Giachetti 1978; Medici

et al. 1999) are age-dependent. Therefore, we wanted to verify that our $Lepr^{db/db}$ model exhibited diabetic physiological properties such as weight gain, elevated blood sugar and serum insulin to verify our diabetic model had sufficient time to develop the phenotype.

Lepr^{db/db} mice are heavier than WT. Mean weights (Figure 2A) for diabetic mice from weeks 10 to 21, increased from 44.1 g (SD = 3.4) to 55.4 g (SD = 5.5), respectively (Holm-Šídák, $p < 0.001$) and were significantly heavier than WT at both time points (Holm-Šídák, $p < 0.001$). In contrast, there was not a statistically significant difference in weight for WT mice from week 10 (M = 18.9, SD = 1.6, g) to 21 (M = 20.0, SD = 1.2, g) (Figure 2A, Holm-Šídák, $p = 0.082$). [Two way ANOVA: Genotype; $F(1, 43) = 169.319$, $p < 10^{-8}$. Age; $F(1, 43) = 21.285$, $p = 3.5 \times 10^{-5}$. Interaction; $F(1, 43) = 3.401$, $p = 0.072$].

Lepr^{db/db} mice are hyperglycemic, especially when young. Surprisingly, in diabetic mice, fasting blood glucose (Figure 2B) significantly decreased from 352.54 mg/dl (SD = 115.22) at week 10 to 196.62 mg/dl (SD = 113.16) at week 21, this phenomena has been reported for C57BL/6J mice before, however, usually at later time points (~week 25-30; although still elevated compared to control (Gunnarsson 1975). Despite this, consistent with the diabetic phenotype, fasting blood glucose was significantly elevated in diabetic mice for both week 10 (Holm-Šídák, $p < 0.001$) and week 21 (HS, $p = 0.044$) vs WT (Figure 2B). In contrast to diabetic mice, no significant difference was observed in the fasting blood glucose of WT mice between weeks 10 (mg/dl, M = 112.47, SD = 27.14) and 21 (M = 107.17, SD = 8.72; Holm-Šídák, $p = 0.901$). [2-way ANOVA: Genotype; $F(1, 43) = 37.150$, $p = 2.7 \times 10^{-7}$. Age; $F(1, 43) = 8.893$, $p = 0.005$. Interaction; $F(1, 43) = 7.762$, $p = 0.008$].

Lepr^{db/db} mice have elevated plasma insulin. In C57BL/6J $Lepr^{db/db}$ mice the plasma insulin level is known to increase (Gunnarsson 1975). Mean plasma insulin levels (Figure 2C) in diabetic mice were stable from week 10 (ng/ml, M = 29.51, SD = 40.19) to week 21 (ng/ml, M = 35.11, SD = 46.51; Holm-Šídák, $p = 0.908$), but were significantly elevated compared to WT (Holm-Šídák, $p < 0.001$) which also did not change from weeks 10 (ng/ml, M = 0.51, SD = 0.43) to 21 (ng/ml, M = 0.33, SD = 0.07; Holm-Šídák, $p =$

0.817). Together, these results support that the $Lepr^{db/db}$ manifests the insulin resistant, type II diabetic phenotype.

Firing properties of $Lepr^{db/db}$ neurons changes with diabetic condition and time

DB10 and DB21 neurons have enhanced and reduced excitability, respectively. Our hypothesis was that since diabetes causes diabetic cystopathy (Kebapci et al. 2007), presumably at least in part through diabetic autonomic dysregulation (Nadelhaft and Vera 1992), $Lepr^{db/db}$ efferent bladder-innervating neurons of the MPG may contribute to these pathological changes and may manifest themselves as changes in intrinsic excitability. Therefore, we first examined whether MPG neurons from different diabetic conditions would spike differently in response to depolarizing current steps from 0 to +700 pA in 50 pA increments (Figure 3A). We used 114 cells from 10-week-old WT mice (WT, n = 37); 5, 10-week-old diabetic mice (DB10, n = 41) and 5, 21-week-old diabetic mice (DB21, n = 36). As we saw no difference in metabolic parameters for WT mice from weeks 10 to 21 (Figure 2), we assume WT physiology is likewise similar to WT21. Thus all WT recordings are made from 10-week old animals. The representative neurons in Figure 3A show that DB10 (Red) neurons appear to be more excitable than WT (Black). In contrast, DB21 neurons (Green) were less excitable than either DB10 or DB21, and appeared to have reduced input resistance (discussed below). Surprisingly, across all conditions, of the 114 neurons studied, only 13 (11.4%) produced more than one spike at any current injection level. Of the neurons that spiked more than once, 76.9% (10/13) were in the DB10 condition compared to a 15.4% (2/13) and 7.7% (1/13) contribution from WT and DB21 groups respectively. The probability of finding a neuron spiking more than once was 5.4% (2/37), 24.4% (10/41) and 2.8% (1/36) for WT, DB10 and DB21 groups respectively. Supporting this difference in excitability, a Chi square test showed that these groups were not statistically independent (χ^2 (2, N = 114) = 8.268, p = 0.016). Similarly; a Kruskal-Wallis showed this data was significantly different, however, this test is more dubious as all groups had median = 1 (Table 1). Due to this low spike probability, we could not run more conventional IO curves. Therefore, instead of IO

curves, we examined the cumulative probability of producing one or more spikes as a function of current injected. A two way ANOVA for factors current and condition showed that cumulative probability of firing 1 or more spikes as a function of injected current was reduced in DB21 condition [Condition; $F(2, 1443) = 37.997$, $p < 1 \times 10^{-8}$. Current; $F(12, 1443) = 51.817$, $p < 1 \times 10^{-8}$. Interaction; $F(24, 1443) = 2.038$, $p = 0.002$]. The probability of a neuron firing at least once (Top, Figure 3C) was not significantly different between DB10 and WT neurons (Holm-Šídák, $p = 0.883$), in contrast, DB21 had reduced probability of firing at least one spike from current injections of 100 to 350 pA when compared to DB10 (Holm-Šídák $p < 0.05$) and from 100 to 400 pA when compared to WT (Holm-Šídák $p < 0.05$). Unfortunately, this particular distribution was neither normally distributed nor homoscedastic due to its binary nature. Supporting the reduced excitability of DB21 neurons was the finding that median rheobase (Left, Figure 3B) was increased in DB21 (Mdn = 300 pA, IQR = 450-200, pA) relative to WT (Mdn = 175, IQR = 262.5-100, pA) (Dunn's test, $p < 0.01$) and DB10 (Mdn = 150, IQR = 250-100, pA) (Dunn's test, $p < 0.01$) [Kruskal Wallis ANOVA on Ranks; $H(2) = 16.181$, $p < 0.001$]. Together, these data support DB21 mice having reduced MPG excitability.

DB10 condition enhances excitability. When examining the probability of these neurons firing twice or more, neurons from DB10 had significantly greater probability of firing more than two spikes compared to both WT and DB21 (Bottom, Figure 3C). This change was significant from current ranges 350-700 pA vs DB21 (Holm-Šídák, $p < 0.05$) and 400-700 pA vs WT (Holm-Šídák, $p < 0.05$) [Condition; $F(2, 1443) = 43.428$, $p < 1 \times 10^{-8}$. Current; $F(12, 1443) = 2.251$, $p = 0.008$. Interaction; $F(24, 1443) = 1.301$, $p = 0.150$]. Median DB10 rheobase (Left, Figure 3B; Mdn 150, IQR = 250-100, pA) was not significantly different from WT (Mdn 150, IQR = 275-100, pA) (Dunn's, $p > 0.05$), but was significantly less compared to DB21 (Mdn 300, IQR = 450-200, pA) (Dunn's, $p < 0.05$) [Kruskal-Wallis, $H(2) = 16.053$, $p < 0.001$]. In agreement with this, DB10 threshold (Center, Figure 3B; Mdn = -25.0, IQR = -20.5-(-30), mV) was hyperpolarized compared to DB21 (Mdn = -19.5, IQR = -15-(-24), mV) (Dunn's test, $p < 0.01$),

however, it was not significantly different from WT (Mdn = -22.0, IQR = -18-(-27.5), mV) but [Kruskal Wallis ANOVA on Ranks; $H(2) = 9.351$, $p = 0.009$]. These results, suggest that DB10 excitability is enhanced relative to WT and DB21 conditions.

Rebound spike latency is decreased in DB10 neurons. Another sign that excitability was increased in DB10 neurons was that latency to first spike after release of hyperpolarizing current injection (Right, Figure 3B) was significantly decreased in the DB10 condition (; Mdn = 7.9, IQR = 13.9-7.1, ms) compared to WT (Mdn = 15.4, IQR = 20.9-11.5, ms)(HS, $p < 0.05$) and DB21 (Mdn = 15.7, IQR = 21.2-14.1, ms) (Holm-Šídák, $p < 0.05$) conditions. These data support excitability being enhanced in the DB10 condition.

Passive properties of diabetic neurons change with age and diabetic condition

In order to characterize the mechanism of observed changes in firing of MPG neurons, we first examined passive properties with the prediction that we should observe depolarized resting membrane potential (RMP) and reduced input resistance in diabetic neurons . In contrast to Tompkins et al. (2013), our data showed no difference in median resting membrane potential (Figure 4A) between WT (Mdn = -43.0, IQR = -36.5-(-47.0), mV) , DB10 (Mdn = -42.0, IQR = -39.5-(-48.5), mV) or DB21 (Mdn = -40.0, IQR = -38.0-(-45.5), mV) (Figure 4A) [Kruskal-Wallis ANOVA on ranks; $H(2) = 2.018$, $p = 0.365$]. However, consistent with Tompkins et al. and our finding of rheobase being increased in DB21, we found that median input resistance (Figure 4B) was significantly reduced in DB21 (Mdn = 42.5, IQR = 51.8-37.3, M Ω) (Dunn's test; $p < 0.004$) but not in DB10 (Mdn = 51.0, IQR = 89.0-38.0, M Ω) (Dunn's test, $p > 0.05$) neurons vs WT (Mdn = 68, IQR = 89.0-44.0, M Ω) neurons [Kruskal-Wallis ANOVA on ranks, $H(2) = 10.641$, $p = 0.005$]. We next estimated time constant by a 2-exponential fit (Golowasch et al. 2009; White and Hooper 2013). Median time constant (Figure 4C) showed a similar pattern, showing a

significant reduction in DB21 (Mdn = 1.8, IQR = 2.5-1.5, ms) compared to WT (Mdn = 2.3, IQR = 3.2-1.6, ms) (Dunn's test, $p < 0.01$), but not compared to DB10 (Mdn = 2.5, IQR = 4.2-1.7, ms)(Dunn's test, $p > 0.05$ [Kruskal-Wallis one way ANOVA on ranks, $H(2) = 6.805$, $p = 0.033$]. Capacitance (Figure 4D) showed a different pattern, where both DB10 (Mdn = 48.7, IQR = 57.8-39.6, pF) and DB21 (Mdn = 41.9, IQR = 54.8-35.1, pF) were significantly increased relative to WT (Mdn = 32.9, IQR = 40.2-29.8, pF) (Dunn's test, $p < 0.01$) [[Kruskal-Wallis one way ANOVA on ranks, $H(2) = 23.187$, $p < 0.001$]. These data suggest that capacitance is increased with diabetic condition independent of time, while time constant and resistance change with diabetic condition and age.

Action potential properties in diabetic neurons change with age.

In order to establish how observed changes in excitability caused by diabetic condition occurred, we examined whether diabetic condition and age modulated properties of the action potentials shown in figure 1.

Ascending spike slope is increased in response to depolarizing current injection in the DB10 condition but not first rebound spike. We looked at ascending action potential slope ($\frac{dv}{dt}$) in response to depolarizing current injections (Figure 1, 9). DB10 mice had significantly greater median ascending spike slope (Figure 5A, Mdn = 30.0, IQR = 52.5-9.5, mv/ms) compared to either WT (Mdn = 8, IQR = 19.0-3.3, mv/ms) (Dunn's Test; $p < 0.01$) or DB21 mice (Mdn = 5, IQR = 20.3-3.0, mv/ms) (Dunn's Test; $p < 0.01$) [Kruskal-Wallis ANOVA on Ranks; $H(2) = 22.365$, $p < 0.001$]. Interestingly, in contrast to evoked spikes, when we examined median maximum ascending slope (i.e. bins of 0.02 ms; Figure 1, 10), in rebound spikes, DB10 neurons (Figure 5C, Mdn = 62.8, IQR = 77.9-40.3, mv/ms) did not significantly differ from WT (Mdn = 55.3, IQR = 77.9-40.3, mv/ms) or DB21 (Mdn = 40.3, IQR = 56.6-25.6, mv/ms)[Kruskal-Wallis ANOVA on Ranks; $H(2) = 5.670$, $p = 0.059$]. We believe this difference was real and not due to a reduction in statistical power, as within WT groups, the coefficient of variance in

ascending slope for depolarizing current injections was greater (CV = 1.14) than for rebound spikes (CV = 0.79). In support of there being no differences in rebound spikes, when ascending spike slope was quantified using a 10-90% rise slope criterion (Figure 1, 7), DB10 neurons (Figure 5G, Mdn = 29.8, IQR = 40.6-15.4, mv/ms) did not significantly differ from either WT (Mdn = 25.8, IQR = 39.5-12.4, mv/ms) or DB21 (Mdn = 20.0, IQR = 32.7-11.5, mv/ms) [Kruskal-Wallis ANOVA on Ranks; $H(2) = 2.043$, $p = 0.360$]. These data support spike slope increasing in the DB10 condition in response to depolarization driven spikes but not rebound spikes.

AP half-width is decreased while decay slope is increased in rebound spikes of DB10 neurons. In contrast to ascending slope, we found that the median width of the action potential at half its maximal height (i.e. half-width; Figure 1, 3) was significantly reduced in the DB10 condition (Figure 5B, Mdn = 3.0 IQR = 3.3-2.4, ms) compared to DB21 (Mdn = 3.7, IQR = 4.4-3.1, ms) (Dunn's test, $p < 0.01$) but not vs WT (Mdn = 3.3, IQR = 4.4-2.6, ms) (Dunn's test, $p > 0.05$) [Kruskal-Wallis ANOVA on Ranks; $H(2) = 14.991$, $p < 0.001$].

Part of the reduction in DB10 half-width may be explained by the finding that that both maximal and 90-10% decay slope increased (Also see discussion). This is shown as median maximal decay slope (Figure 5D) was made more negative (increased) in DB10 neurons (Mdn = -20.0, IQR = -14.7-(-24.6), mv/ms) vs DB21 neurons (Mdn = -13.4, IQR = -9.7-(-18.9), mv/ms) (Dunn's test, $p < 0.05$) but not vs WT (Mdn = -16.0, IQR = -11.3-(-22.1), mv/ms) (Dunn's test, $p > 0.05$) neurons [Kruskal-Wallis ANOVA on Ranks; $H(2) = 8.112$, $p = 0.017$] suggesting these neurons repolarized faster. In agreement with this, mean 90-10% decay slope (Figure 5H) also became more negative in the DB10 condition (M = -16.7, SD = 5.3, mv/ms) vs WT (M = -12.4, SD = 5.6, mv/ms) (Holm Sidak, $p = 0.001$) and compared to DB21 (M = -11.0, SD = 4.2, mv/ms) (Holm-Sidak, $p < 0.001$) [One way ANOVA; $F(2, 100) = 11.541$, $p = 3.1 \times 10^{-5}$]. Accordingly, median 90-10% decay time (Figure 5F) significantly decreased in DB10 (Mdn = 2.7, IQR = 3.1-2.5, ms) vs WT (Mdn = 3.7, IQR = 4.8-3.0, ms) (Dunn's test, $p < 0.01$) and DB21 (Mdn = 4.4, IQR = 5.0-3.5, ms) (Dunn's test, $p < 0.01$) [Kruskal-Wallis ANOVA on Ranks; $H(2) = 42.223$, $p <$

0.001]. This data, in combination with the finding that AP ascending slope did not increase in rebound spikes, suggests that AP half-width decreased primarily through a mechanism that increases AP descending slope.

AP area and AHP decay constant decreased in DB10 with no changes in after hyperpolarization (AHP) area. Consistent with decreased AP half-width, total AP area (excluding the AHP; Figure 5I) was significantly decreased in DB10 neurons (Mdn = 174.4, IQR = 238.8-142.7, mV·ms) relative to DB21 (Mdn = 232.5, IQR = 266.7-217.5, mV·ms) (Dunn's test, $p < 0.05$) but not when compared to WT (Mdn = 209.8, IQR = 290.7-172.0, mV·ms) (Dunn's test, $p > 0.05$) [Kruskal-Wallis ANOVA on Ranks; $H(2) = 12.320$, $p = 0.002$]. This was not due to changes in spike height, as neither DB10 (Mdn = 63.6, IQR = 78.1-37.9, mV) nor DB21 (Mdn = 61.2, IQR = 75.9-53.8, mV) differed significantly in spike height (Table 1) relative to WT (Mdn = 64.5, IQR = 80.1-52.7, mV) [Kruskal-Wallis ANOVA on Ranks; $H(2) = 0.498$, $p = 0.779$]. If AP area decreased, a possible mechanism would be activation of outward currents, and one might expect to see an enhanced AHP. However, no change in AHP area (Figure 5J) for DB10 (Mdn = -141.6, IQR = -88.1-(-259.2), mV·ms), nor DB21 (Mdn = -121.9, IQR = -92.1-(-200.5), mV·ms) vs WT (Mdn = 116.6, IQR = -80.6-(-251.1), mV·ms) was observed [$H(2) = 0.530$, $p = 0.767$]. Neither were changes were observed in AHP height (figure 1, 2) in DB21 (Figure 5K, Mdn = -10.0, IQR = -5.8-(-12.9), mv), DB10 (Mdn = -11.6, IQR = -7.7-(-15.4), mv) conditions vs WT (Mdn = -12.4, IQR = -8.5-(-15.9), mv) [Kruskal-Wallis ANOVA on Ranks; $H(2) = 2.900$, $p = 0.235$]. Despite our finding of stable AHP amplitude and area, we did see that AHP decay tau significantly decreased in DB10 neurons (Mdn = 13.0, IQR = 16.5-10.5, ms) vs WT (Mdn = 16.9, IQR = 21.2-16.9, ms) (Dunn's, $p < 0.01$) and DB21 (Mdn = 17.0, IQR = 20.0-13.4, ms) (Dunn's, $p < 0.05$) (Figure 5L) [Kruskal-Wallis ANOVA on ranks; $H(2) = 11.896$, $p = 0.003$]. These data suggest that diabetic condition and age affect interact to alter AP area and AHP decay constant while leaving other AP parameters unmodified.

2nd AHPs and ADPs after 145 ms. When quantifying properties of the AHP, it was found that after the initial AHP, some neurons had after depolarizations, while some had secondary slower AHPs

and still others had both. We attempted to systematically quantify this across conditions by analyzing the change in voltage 145 ms after the descending stroke of the AP recrossed baseline. However, this comes with the caveat that some neurons could not be quantified due to no change in baseline, multiple rebound spikes, or loss of cells. Within 73.0 % (27/37) of quantified WT neurons, 81.5% (22/27) displayed afterdepolarizations, while the remaining 18.5% (5/27) displayed secondary after hyperpolarizations and none displayed both. Within DB10 neurons 4.9% (2/41) could not be classified due to multiple rebound spikes. However, of the 82.9% (34/41) that could be quantified, 44.1% (15/34) showed ADPs, 20.6% (7/34) showed secondary AHPs; in contrast to WT; where 29.4% (10/34) of these neurons showed both AHPs and ADPs. Within 94.4% (34/36) of quantified DB21 neurons, 76.5% (26/34) showed ADPs, 2.9% (1/34) showed secondary AHPs, while 20.6% (7/34) showed both. A Chi Square test showed that these groups were statistically independent (χ^2 (4, N = 95) = 15.960, p = 0.003). Alternatively, when we just quantified the absolute voltage change at 145 ms, DB10 (Mdn = -0.2, IQR = 2.0-(-0.7), Δ mV) (Dunn's, p < 0.05) but not DB21 (Mdn = 0.8, IQR = 1.8-0.9, Δ mV) (Dunn's, p > 0.05) was significantly different from WT (Mdn = 1.8, IQR = 3.8-0.9, Δ mV) (Table 1) [Kruskal-Wallis ANOVA on Ranks; H (2) = 10.766, p = 0.005]. This data suggests that the DB10 condition is more likely to have slow AHPs or a lack of ADPs relative to WT.

Ion Channels Show Widespread Changes in Expression in Both DB10 and DB21 Animals

We specifically focused on subsets of ion channel and receptor genes for this study to start to understand the underlying mechanisms for changes in excitability that we detected in MPG neurons of diabetic animals. We sampled alpha subunits for voltage-dependent Ca^{2+} channels (*CACNA1A-H*), a subset of Na^{+} channels (*SCNx*), and six families of K^{+} channels (*KCNA*, *KCNB*, *KCNC*, *KCND*, *KCNN*, *KCNMA*). Of 30 ion channel genes studied, 8 were significantly different between DB10 and control wild-type animals (Figure 6). The voltage-dependent Ca^{2+} channels *CACNA1A*, *CACNA1E* and *CACNA1H* were significantly higher in DB10 animals relative to control. The only Na^{+} channel gene that

was changed was a significant increase in *SCN2A1* in DB10 animals. In addition, 4 K⁺ channel genes showed altered expression in DB10 animals: *KCNA3* was significantly lower in DB10 animals, while *KCNB1*, *KCNC2*, and *KCND3* were significantly higher in DB10 mice.

In DB21 animals, 12 channel genes showed differential expression relative to wild-type controls (Figure 6). *CACNA1D* and *CACNA1G* were significantly higher in DB21 animals relative to control. There were no significant differences in sodium channel gene expression seen between DB21 and wild-type animals. However, there were 10 different K⁺ channel genes that showed changes in expression in DB21 animals. *KCNA2*, *KCNA3*, *KCNA5*, and *KCNC3* all were significantly lower in DB21 animals than wild-type, with *KCNA2* and *KCNC3* expression all but abolished in the DB21 animals. *KCNC4*, *KCND2*, *KCND3*, *KCNN1*, *KCNN3* and *KCNMA1* were all significantly higher in DB21, with *KCND2* expression only detectable in DB21 animals. Most of these changes are seen only in DB21 animals and not in DB10, including *KCNA2*, *KCNA5*, *KCNC3*, *KCNC4*, *KCND2*, *KCNN1*, *KCNN3* and *KCNMA1*.

Some changes seen in DB10 animals resolve to control levels in the DB21 animals, while others persist throughout the DB21 time point (Figure 6). *KCNA3* is significantly lower in DB10 animals, and this change persists into the DB21 group. *KCND3* is significantly increased in both DB10 and DB21 animals. Conversely, *KCNB1* is significantly higher in the DB10 animals, but returns to control levels in DB21 animals. Finally, there are some channels that are significantly different only between DB10 and DB21. *KCNA1* and *KCND1* are significantly higher in DB21 than DB10, although there is a trend towards these two channels being downregulated in DB10 overall, even though this does not reach statistical significance relative to control. The converse is true for *KCNB2*, which is significantly higher in DB10 than DB21 – although there is a trend for this channel to be transiently upregulated in the DB10 group.

Principal Components Analysis to Further Examine Differences Among Groups in Firing Properties and Channel Expression

We next used principal component analysis (PCA) to visualize potential patterns and correlations in the features that may underlie distinctions in both the spike properties and channel expression across groups. A variance plot of the first two principal components (PC) for spike characteristics (Figure 7A) demonstrates that there is overlapping features in all three groups that do not distinguish these groups in any obvious way. There is one major PC (PC1) that accounts for the majority of the variance in the data (42.5%, Figure 7B). The variables that most contribute to the variance in spike characteristics largely consist of features involved in shaping the action potential dynamics underlying spike shape, such as decay slope, rise slope, and the amplitude of the spike (e.g. spike height, peak amplitude). These would be consistent with changes in Na⁺ and K⁺ channel expression, particularly those subtypes involved in the spiking itself. However, there is no combination of features that separates the diabetic animals from the wild-types, or each other, in a discrete fashion.

The PCA for channel expression in the MPG tells a different story. The variance plot of PC1 and PC2 (Figure 8A) shows clear separation of all three groups, and the scree plot (Figure 8B) notes that these two PCs account for the majority of the variance in the data. When looking at the channels that contribute to PC1 and PC2, it is also clear validation of the changes in expression reported in Figure 6. By examining the vector plot in Figure 8A and the contributions to PC1 in Figure 8B, it is possible to discriminate a group of channels largely responsible for distinguishing the DB21 animals. The top ten contributors to PC1 consists entirely of channels that are uniquely differentially expressed in DB21 animals relative to both DB10 and control. Conversely, by examining the top ten contributors to PC2 – in conjunction with the vector plot – it can be seen that PC2 consists of channels uniquely differentially expressed in DB10 animals (*CACNA1A*, *CACNA1E*, *SCN2A1*, *KCNB1*, *KCNC2*) as well as channels that are both changed in the same direction in DB10 and DB21 (*KCND3*).

DISCUSSION

Diabetic cystopathy has formally been documented since 1864 (Faerman et al. 1971), yet the only direct attempt to document how diabetes impacts efferent bladder innervating neurons was by Tompkins et al., (2013) who focused largely on synaptic properties. Therefore, in this study we attempted to identify for the first time the impacts of a type II diabetes model on the intrinsic properties of bladder-innervating parasympathetic neurons in female mice. We hypothesized that passive properties, overall excitability and action potential properties in MPG neurons would change in an age-dependent manner within the diabetic condition. Furthermore, we examined underlying changes in mRNA levels for voltage-dependent ion channels in the whole ganglion as a reflection of the most salient of changes in excitability and firing of MPG neurons.

$Lepr^{db/db}$ mice on the C57Bl6/J strain used here model hyperglycemia and persistent hyperinsulinemia with beta cell hypertrophy, whereas those on the BKS background strain progress to beta cell failure (Hummel et al. 1972). Although the mice in this study were diabetic at both ages, their hyperglycemia was somewhat worse at 11 weeks than at 21 weeks, consistent with previous observations in this strain (Breyer et al. 2005; Sullivan et al. 2007). This improvement was consistent with the constant, or slightly increasing serum insulin concentrations at 21 weeks, indicating that while the beta cells are not able to adequately compensate for insulin resistance, they have not undergone beta cell failure.

Diabetes interacts with time to first increase then decrease MPG neuron excitability

One of our most important findings was that excitability of MPG neurons in $Lepr^{db/db}$ females changes nonlinearly with the amount of time exposed to the diabetic environment. Specifically, we observed that 10 week $Lepr^{db/db}$ mice had an increased probability of firing two or more spikes, and decreased rebound spike latency; both of which are measures of increased overall neuronal excitability. In contrast, week 21

$Lepr^{db/db}$ neurons changed in the opposite direction, exhibiting a decrease in spike probability and increased rheobase, both of which are indications of lower overall excitability. This trend of a change in firing properties at 10 weeks that is then rectified at 21 weeks is also seen in the characteristics of action potentials of MPG neurons. Specifically, spikes are narrower (as seen by a decreased half-width, increased ascending slope and enhanced decay slope, and decreased decay time in DB10 animals), and AHPs are shorter in the DB10 animals but return to control levels in the DB21 group. These data are consistent with the hypothesis that long-term diabetes results in change in MPG neuron that potentially are compensated for via long-term plasticity mechanisms in the DB21 animals. Regardless of whether the changes in excitability and action potential properties are compensatory or represent disease progression in the context of the entire LUT, there is clear change in the characteristics of MPG neurons over the course of 10-21 weeks in diabetic animals.

Because normal bladder function and diabetic cystopathy are the result of a complex interaction of the activities of sympathetic, parasympathetic, and sensory feedback mechanisms combined with bladder compliance and detrusor properties, it is not possible to interpret our results directly in context of mechanisms of changes in bladder output as a result of diabetes. However, the time course of changes in MPG neuron excitability mirror those of bladder output over the progression of diabetic cystopathy in rodents. For example, in type I diabetic mice there is a sharp decline in basal bladder pressure and mean threshold pressure from weeks 9-12 that then is rectified to control levels by 20 weeks (Daneshgari et al. 2006a). Similar time course changes in bladder output features as measured by cystometrograms have been documented in rats as well, whereby diabetic bladders transition from compensated to decompensated states between 9-12 weeks following onset of diabetes (Daneshgari et al. 2006b). Therefore, while a direct mechanistic link to bladder output cannot be made from our data, the results are consistent with the overall change in LUT output over the time course of diabetic cystopathy.

Potential mechanistic insights via interpretation of changes in mRNA levels

It would be an over-interpretation to directly infer mechanisms underlying physiological changes in single neurons from data collected at the mRNA level from whole ganglia. However, the steady-state mRNA levels for ion channels provide a high-throughput opportunity to generate hypothesis regarding underlying mechanistic changes in ionic currents. Indeed, we see multiple changes in channel mRNAs that are consistent with the physiological changes we report. In this section, we will highlight some of the most salient changes we found at the level of neuronal properties, and cautiously hypothesize on potential underlying mechanism via changes at the mRNA level.

In 10-week *Lepr^{db/db}* mice we observed that although rheobase did not change, several properties associated with excitability did change. The most salient of these properties was the increase of the probability of firing 2 or more spikes. As shown in Figure 3A and also previously documented (Suzuki and Rogawski 1989; Tompkins et al. 2013), MPG neurons can spike once or many times, a phenomena observed in many other autonomic neuron types (Cassell et al. 1986; Malin and Nerbonne 2001; Springer et al. 2015). One obvious possible mechanism for generating multiple spikes is the activation of a depolarizing current with somewhat slower kinetics that can maintain depolarization above threshold to allow for the generation of multiple spikes. Our data show changes in channel expression that are consistent with this hypothesis. In particular, there is a significant increase in mRNA levels for the calcium channels *CACNA1A*, *CACNA1E*, and *CACNA1H* in DB10 animals relative to both WT and DB21. Furthermore, *CACNA1E* levels overall are the most abundant calcium channel mRNA that we detected, with levels an order of magnitude higher than any other calcium channel subunit. *CACNA1E* encodes the R-type current $Ca_v2.3$, which is known to make up ~25% of total calcium current in rat MPG neurons (Won et al. 2006), and $Ca_v3.2$ – encoded by *CACNA1H* – is the predominant T-type channel in rat MPG (Lee et al. 2002). R-type currents are known to influence bursting output in CA1 pyramidal neurons (Metz et al. 2005), and T-type currents in many neurons trigger low-threshold spikes, which in turn generate bursts of action potentials (Perez-Reyes 2003). While the interplay of multiple calcium channel subunits and the remaining ionic conductances of the cell are quite complex in terms of

generating different output patterns, increases in R-type and T-type currents would be a feasible way to influence the multiple spiking phenotype in DB10 animals.

We also observed increased ascending and descending spike slopes, and decreased spike half-width in the DB10 animals relative to WT and DB21. We observed increased expression of mRNAs coding for $\text{Na}_v1.2$ (*SCN2A1*), as well as a trend for increased $\text{Na}_v\beta1$ (*SCN1B*) expression, in the DB10 animals. $\text{Na}_v1.2$ channels are largely localized to the axons and initial segments of unmyelinated neurons (Vacher et al. 2008), which is consistent with the post-ganglionic fibers of the MPG. $\text{Na}_v\beta1$ is known to interact with $\text{Na}_v1.2$ channels to increase surface expression of these subunits (Isom et al. 1995). Therefore, increases in expression of *SCN2A1* and *SCN1B* would be expected to increase AP upstroke, which was observed for depolarizing current injections but not rebound spikes. In addition, $\text{K}_v3.2$ and $\text{K}_v2.1$ are potassium channels with relatively high threshold activation and fast deactivation such that they have both been implicated as large contributors to the AP repolarization and as a consequence decrease AP width (Rudy and McBain 2001; Liu and Bean 2014). The upregulation of their constituent mRNA subunits (*KCNC2* and *KCNB1* respectively) is entirely consistent with the firing phenotypes observed.

As we observed increases in ascending spike slope to depolarizing current injections, but not rebound current injections in DB10 neurons, it is possible that high threshold potassium currents with fast deactivation time constants could play a role in permitting multiple spikes during depolarizing current injections by enhancing sodium channel de-inactivation. As K_v2 family members are known to encode delayed rectifiers, and K_v3 channels have fast activation and deactivation rates associated with sustained higher-frequency firing, then the fact that we see increased $\text{K}_v3.2$ (*KCNC2*) and $\text{K}_v2.1$ (*KCNB1*) expression is also consistent with these results. While this is well documented for $\text{K}_v3.2$ as it is a high threshold, fast deactivating (Weiser et al. 1994; Rudy and McBain 2001) ion channel, it is less clear that this is the case for $\text{K}_v2.1$ as it is intermediate in these parameters. For example, in the superior cervical ganglion (SCG) neurons, $\text{K}_v2.1$ has somewhat high $V_{1/2}$ activation, slow activation, slow or no inactivation, but a relatively fast deactivation (Liu and Bean 2014). If $\text{K}_v2.1$ is playing a role in keeping

the functional pool of sodium channels available through de-inactivation, as it is thought to do in SCG neurons (Liu and Bean 2014), then we expect its upregulation should prevent decay in spike height during a train of spikes. Therefore, to test this prediction, we examined the ratio of the 2nd to 1st spike height of multi-spiking neurons. A t-test showed that 2nd to 1st spike ratio of DB10 neurons (0.79 ± 0.03 , $n = 8$) were significantly less attenuated than WT neurons (0.48 ± 0.11 , $n = 2$) ($t(8) = -4.416$, $p = 0.002$). This suggests that together $K_v3.2$ and $K_v2.1$ could play a role in keeping sodium currents de-inactivated in the DB10 condition.

DB21 neurons were significantly less excitable than both DB10 and wild type neurons: rheobase was significantly increased, and input resistance was significantly reduced compared to wildtype, and DB21 neurons did not produce a multi-spiking output when stimulated. DB21 neurons had significantly upregulated mRNAs encoding several low threshold slow deactivating potassium currents that would be expected to reduce excitability. The upregulation of *KCNA1* ($K_v1.1$) likely contributes to reduced excitability given a relatively low threshold of activation (~ -32 mV) and intermediate deactivation time constant (Grissmer et al. 1994). The upregulation of *KCND2* ($K_v4.2$) is consistent with the observed decrease in excitability and may explain in part why the DB21 condition did not share the multispiking phenotype with DB10. This is because in cultured rat superior cervical ganglion neurons, Malin and Nerbonne (2000) showed that when $K_v4.2$ is overexpressed, the number of neurons displaying the multi-spiking neuron phenotype is decreased, and when the gene is downregulated by expression of a dominant negative transgene, there is a corresponding increase in the multi-spiking phenotype. Interestingly, the authors also report increased input resistance in cells with reduced $K_v4.2$, and decreased input resistance with overexpression of $K_v4.2$ (Malin and Nerbonne 2001) which is consistent with the significant decrease in R_{in} in DB21 neurons.

Conclusions

We expected excitability of $\text{Lepr}^{\text{db/db}}$ neurons to change with increasing intensity from weeks 10 to 21 as diabetes progressed as diabetic neuropathy is a function of both hyperglycemia and duration in humans (Maser et al. 1989; Davies et al. 2006), rats (Mattingly and Fischer 1983; Sasaki et al. 2002) and mice (Giachetti 1978; Hinder et al. 2017; Liu et al. 2017). Contrary to this hypothesis, many properties associated with excitability changed in 10-week animals, but were then resolved closer to wild-type levels in the 21-week animals. These properties include both characteristics of intrinsic excitability (e.g. probability to fire, threshold, and rebound latency) as well as many of the characteristics of the individual action potentials of these neurons as well. Yet, our expression profiling of the MPGs does not simply reveal a resolution at 21-weeks of changes in expression that occur in the 10-week animals. Rather, our PCA reveals that the overall expression patterns in MPGs of wild type, 10-week, and 21-week animals are entirely distinct. Taken together, we suggest that these results represent an apparent compensatory response, where neurons of the MPG in younger diabetic mice are less adapted to hyperglycemia, or the associated bladder cystopathy, than older diabetic mice that have been exposed to hyperinsulinemia for longer times.

TABLES

Table 1. Non-parametric (non-normal or non-homoscedastic) negative or redundant statistical summary † Internal control that is best fit line to sampled interval. ‡ n was 27, 32, 34 for WT, DB10 and DB21 respectively.

Property (units)	WT n = 35			DB10 n = 34			DB21 n = 34			Kruskal-Wallis p =
	Mdn.	75 th per.	25 th per.	Mdn.	75 th per.	25 th per.	Mdn.	75 th per.	25 th per.	
1 st spike latency at depolarizing rheobase (ms)	14.2	17.7	10.8	13.9	17.6	12.2	15.3	18.3	11.7	0.793
1 st spike latency for Rebound spikes (-500 pA)	15.2	22.3	11.6	7.9	13.9	7.9	15.7	21.2	14.1	<0.001
Baseline slope (mV/ms) [†]	-0.3	-0.2	-0.5	-0.3	-0.1	-0.4	-0.2	-0.1	-0.4	0.424
Time from spike peak to AHP peak (ms)	8.3	11	7.3	6.9	7.5	6.1	9.8	11.2	8.1	<0.001
Spike Height (mV)	64.5	80.1	52.7	63.6	78.1	37.9	61.2	75.9	53.8	0.779
Max Spikes (spikes)	1.0	1.0	1.0	1.0	1.5	1.0	1.0	1.0	1.0	0.004
Rebound spikes (-500 pA; spikes)	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.628
Change in Membrane potential 145 ms after AP repolarization (mV) ‡	1.8	3.8	0.9	-0.2	2.0	-0.7	0.8	1.8	0.2	0.005

Table 2. Negative or redundant statistical summary that was normal and homoscedastic. † Internal control that is essentially the RMP right after rebound. ‡ Redundant with area ($\frac{1}{T} \int_{t_0}^{t_0+T} Area$)

Property (units)	WT	DB10	DB21	One- way ANOVA p =
	Mean (SD) n = 35	Mean (SD) n = 34	Mean (SD) n = 34	
AP Mean Height, (mV) ‡	1.8 (2.5)	0.7(1.7)	1.7(1.6)	0.045
Baseline (mV) [†]	-41.0 (7.8)	-41(7.6)	-38.8(5.9)	0.378

FIGURE LEGENDS

Figure 1. Action potential properties measured from depolarization and rebound induced spikes.

Each number corresponds to a given measurement, as described in the Methods. These numbers are referred to in the Results section when relevant.

Figure 2. *Lepr^{db/db}* mice show a strong diabetic phenotype at week 10 with hyperglycemia that is somewhat reduced at week 21. Diabetes associated metabolic parameters of DB vs WT mice at different times; week 10 (*left*) or week 21 (*right*) in either wildtype (white) or diabetic conditions (red and green for weeks 10 and week 21 respectively). **A.** A two-way ANOVA for factors genotype and age showed that mouse weight was influenced by genotype and age. [Genotype; $F(1, 43) = 169.319$, $p < 10^{-8}$. Age; $F(1, 43) = 21.285$, $p = 3.5 \times 10^{-5}$. Interaction; $F(1, 43) = 3.401$, $p = 0.072$] **B.** A two-way ANOVA for factors genotype and age showed that fasting blood glucose was influenced by genotype and age. [Genotype; $F(1, 43) = 37.150$, $p = 2.7 \times 10^{-7}$. Age; $F(1, 43) = 8.893$, $p = 0.005$. Interaction; $F(1, 43) = 7.762$, $p = 0.008$]. **C.** Two-way ANOVA for factors genotype and age showed that fasting serum insulin was influenced by genotype. [Genotype; $F(1, 43) = 71.608$, $p < 10^{-8}$. Age; $F(1, 43) = 0.0595$, $p = 0.809$. Interaction; $F(1, 43) = 0.0113$, $p = 0.916$]. Holm-Sidak Post-Hoc test; *, $p < 0.05$; **, $p < 0.01$. Error bars are SEM.

Figure 3. DB10 and DB21 conditions increase and decrease excitability of MPG neurons, respectively. **A.** Representative traces of intracellular currents injections of -500 pA, 100 pA and 500 pA current injections in WT10 (black), DB10 (red) or DB21 (green). **B. Left:** Kruskal-Wallis one way ANOVA on ranks showed that rheobase was significantly altered by diabetic condition [$H(2) = 16.053$, $p < 0.001$]. **Center:** A Kruskal-Wallis one way ANOVA on ranks showed that threshold (Figure 1, 12) was significantly altered by diabetic condition [$H(2) = 9.351$, $p = 0.009$]. **Right:** Kruskal-Wallis one way ANOVA on ranks showed that diabetic condition significantly altered latency to rebound spike [$H(2) = 22.897$, $p < 0.001$]. Shown are Medians, quartiles and outliers. Dunn's test; *, $p < 0.05$; **, $p < 0.01$. ***, $p < 0.001$. **C. Top:** Two-way ANOVA for factors current and condition showed that cumulative

probability of firing 1 or more spikes as a function of injected current was reduced in DB21 condition [Condition; $F(2, 1443) = 37.997$, $p < 1 \times 10^{-8}$. Current; $F(12, 1443) = 51.817$, $p < 1 \times 10^{-8}$. Interaction; $F(24, 1443) = 2.038$, $p = 0.002$.]. *Bottom*: A two-way ANOVA showed that the Cumulative probability of firing 2 or more spikes as a function of injected current was increased in the DB10 condition [Condition; $F(2, 1443) = 43.428$, $p < 1 \times 10^{-8}$. Current; $F(12, 1443) = 2.251$, $p = 0.008$. Interaction; $F(24, 1443) = 1.301$, $p = 0.150$.]. Note difference in scale. Holm-Sidak post hoc tests: $p < 0.05$; * WT10 vs DB10, † WT10 vs DB21, ‡ DB10 vs DB21. Shown are Means $\pm$ SEM.

Figure 4. Effect of condition for WT, DB10, and DB21 condition on passive properties of MPG neurons.

A. A Kruskal-Wallis one-way ANOVA on ranks showed that diabetic condition did not affect resting membrane potential (RMP) [$H(2) = 2.017$, $p = 0.365$]. **B.** A Kruskal-Wallis one-way ANOVA on ranks showed that diabetic condition altered input resistance (R_{in}) [$H(2) = 10.641$, $p = 0.005$]. **C.** A Kruskal-Wallis one way ANOVA on ranks showed that diabetic condition altered membrane time constant [$H(2) = 6.805$, $p = 0.033$]. **D.** A Kruskal-Wallis one-way ANOVA on ranks showed that diabetic condition altered capacitance of MPG neurons [$H(2) = 23.187$, $p < 0.001$]. Data shown are medians, quartiles and outliers. Dunn's test: * $p < 0.05$; **, $p < 0.01$.

Figure 5. Action potential (AP) parameters are altered by DB condition in mouse MPG neurons. AP

properties illustrated in figure 1 were quantified in 10 week wildtype (Black), 10 week Diabetic (Red) and 21 week diabetic (Green) in mouse MPG neurons. All data except A were quantified from rebound spikes. **A.** A Kruskal-Wallis one way ANOVA on ranks showed that diabetic condition affected ascending spike slope elicited by depolarizing current injection (Figure 1, 9) during depolarizing current injection of MPG neurons [$H(2) = 22.010$, $p < 0.001$]. **B.** A Kruskal-Wallis one way ANOVA on ranks showed that diabetic condition affected AP half-width (Figure 1, 3) [$H(2) = 14.892$, $p < 0.001$]. **C.** A Kruskal-Wallis one way ANOVA on ranks showed that diabetic condition did not significantly alter AP maximum rise slope (Figure 1, 10) [$H(2) = 5.670$, $p = 0.059$]. **D.** A Kruskal-Wallis one way ANOVA on ranks showed that diabetic condition altered maximum AP decay slope of (Figure 1, 11) [$H(2) = 8.112$, p

= 0.017]. **E.** A Kruskal-Wallis one way ANOVA on ranks showed that diabetic condition altered AP 10-90% rise time (Figure 1, 4) [$H(2) = 6.464$, $p = 0.039$]. **F.** A Kruskal-Wallis one way ANOVA on ranks showed that diabetic condition altered 90-10% decay time (Figure 1, 5) [$H(2) = 42.223$, $p < 0.001$]. **G.** A Kruskal-Wallis one way ANOVA on ranks showed that diabetic condition did not alter AP 10-90% rise slope (Figure 1, 7) [$H(2) = 2.043$, $p = 0.360$]. **H.** A one-way ANOVA showed that diabetic condition altered 90-10% decay slope (Figure 1, 8) [$F(2, 101) = 11.541$, $p = 3.1 \times 10^{-5}$]. **I.** A Kruskal-Wallis one-way ANOVA on ranks showed that diabetic condition altered AP area (Figure 1, 6) [$H(2) = 12.320$, $p = 0.002$]. **J.** A Kruskal-Wallis one-way ANOVA on ranks showed that diabetic condition did not alter AHP area (Figure 1, 13) [$H(2) = 0.530$, $p = 0.767$]. **K.** A Kruskal-Wallis one-way ANOVA on ranks showed that diabetic condition did not alter AHP amplitude (Figure 1, 2) [$H(2) = 2.900$, $p = 0.235$]. **L.** A Kruskal-Wallis one way ANOVA on ranks showed that diabetic condition altered AHP decay tau (Figure 1, 14) [$H(2) = 11.896$, $p = 0.003$]. Data shown are medians, quartiles and outliers. Dunn's test: * $p < 0.05$; **, $p < 0.01$.

Figure 6. mRNA copy numbers for ion channel subunits of across WT, DB10, and DB21

experimental groups. Significant differences as noted ($p < 0.05$; post-hoc Holm-Šídák analyses following One-Way ANOVA) represent pairwise comparisons across all three groups. Data shown are medians, quartiles and each individual value from a given animal.

Figure 7. Principal components analysis (PCA) of spike characteristic across WT, DB10, and DB21

mice. A. The first two principal components (PC1 and PC2) define the x-and y-axes respectively. PC1 accounted for 42.5% of the variance while PC2 accounted for 14.6%. By and large, all three groups show overlapping distribution of variance across PC1 and PC2. **B.** Scree plot demonstrating the amount of variance accounted for across the first 10 principal components. A substantial plurality of the variance is accounted for in the first principal component, while the remainder contribute far less to the variance in the data. **C.** Post-hoc analysis of the variables that contribute to the variance in PC1 reveals that relatively equal contributions are found from variables associated with spike shape and AHP amplitude.

Figure 8. PCA of ion channel mRNA levels across WT, DB10, and DB21 mice. **A.** The first two principal components (PC1 and PC2) define the x-and y-axes respectively. PC1 accounted for 25.6% of the variance while PC2 accounted for 21.9%. The distribution across PC1 and PC2 reveals three distinct ion channel expression profiles for WT, DB10, and DB21 animals. **B.** Scree plot demonstrating the amount of variance accounted for across the first 10 principal components. The majority of the variance is accounted for in the PC1 and PC2, while the remainder contribute far less to the variance in the data. **C.** Post-hoc analysis of the variables that contribute to the variance in PC1 and PC2 reveals distinct channel subunits that account for the distinct patterns of expression seen in all three experimental groups.

REFERENCES

- Breyer MD, Bottinger E, Brosius 3rd FC, Coffman TM, Harris RC, Heilig CW, Sharma K, Amdcc.** Mouse models of diabetic nephropathy. *J Am Soc Nephrol* 16: 27–45, 2005.
- Cassell JF, Clark AL, McLachlan EM.** Characteristics of phasic and tonic sympathetic ganglion cells of the guinea-pig [Online]. *J Physiol* 372: 457–483, 1986. <http://www.ncbi.nlm.nih.gov/pubmed/2425087>.
- Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP.** Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice [Online]. *Cell* 84: 491–495, 1996. <http://www.ncbi.nlm.nih.gov/pubmed/8608603>.
- Daneshgari F, Huang X, Liu G, Bena J, Saffore L, Powell CT.** Temporal differences in bladder dysfunction caused by diabetes, diuresis, and treated diabetes in mice. *Am J Physiol Regul Integr Comp Physiol* 290: R1728–35, 2006a.
- Daneshgari F, Liu G, Imrey PB.** Time Dependent Changes in Diabetic Cystopathy in Rats Include Compensated and Decompensated Bladder Function. *J Urol* 176: 380–386, 2006b.
- Davies M, Brophy S, Williams R, Taylor A.** The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. *Diabetes Care* 29: 1518–1522, 2006.
- DCCT Research Group the.** The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial [Online]. *Diabetes* 45: 1289–1298, 1996. <http://www.ncbi.nlm.nih.gov/pubmed/8826962>.
- Faerman I, Maler M, Jadzinsky M, Alvarez E, Fox D, Zilbervarg J, Cibeira JB, Colinas R.** Asymptomatic neurogenic bladder in juvenile diabetics [Online]. *Diabetologia* 7: 168–172, 1971. <http://www.ncbi.nlm.nih.gov/pubmed/5560918>.
- Frimodt-Moller C.** Diabetic cystopathy: epidemiology and related disorders [Online]. *Ann Intern Med* 92: 318–321, 1980. <http://www.ncbi.nlm.nih.gov/pubmed/7356221>.
- Garcia VB, Abbinati MD, Harris-Warrick RM, Schulz DJ.** Effects of chronic spinal cord injury on relationships among ion channel and receptor mRNAs in mouse lumbar spinal cord. *Neuroscience* submitted, 2018.
- Garcia VB, Garcia ML, Schulz DJ.** Quantitative expression profiling in mouse spinal cord reveals changing relationships among channel and receptor mRNA levels across postnatal maturation. *Neuroscience* 277: 321–333, 2014.
- Giachetti A.** The functional state of sympathetic nerves in spontaneously diabetic mice [Online]. *Diabetes* 27: 969–974, 1978. <http://www.ncbi.nlm.nih.gov/pubmed/700260>.
- Golowasch J, Thomas G, Taylor AL, Patel A, Pineda A, Khalil C, Nadim F.** Membrane capacitance measurements revisited: dependence of capacitance value on measurement method in nonisopotential neurons. *J Neurophysiol* 102: 2161–2175, 2009.
- Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA, Karmilowicz MJ, Auperin DD, Chandy KG.** Pharmacological characterization of five cloned voltage-gated K⁺ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines [Online]. *Mol Pharmacol* 45: 1227–1234, 1994. <http://www.ncbi.nlm.nih.gov/pubmed/7517498>.
- Gunnarsson R.** Function of the pancreatic B-cell during the development of hyperglycaemia in mice

742 homozygous for the mutations “diabetes” (db) and “misty” (m) [Online]. *Diabetologia* 11: 431–438,
743 1975. <http://www.ncbi.nlm.nih.gov/pubmed/1103367>.

744 **Hanani M.** Satellite glial cells in sympathetic and parasympathetic ganglia: in search of function. *Brain*
745 *Res Rev* 64: 304–327, 2010.

746 **Hinder LM, O’Brien PD, Hayes JM, Backus C, Solway AP, Sims-Robinson C, Feldman EL.** Dietary
747 reversal of neuropathy in a murine model of prediabetes and metabolic syndrome. *Dis Model Mech* 10:
748 717–725, 2017.

749 **Hummel KP, Coleman DL, Lane PW.** The influence of genetic background on expression of mutations
750 at the diabetes locus in the mouse. I. C57BL-KsJ and C57BL-6J strains [Online]. *Biochem Genet* 7: 1–13,
751 1972. <http://www.ncbi.nlm.nih.gov/pubmed/4557514>.

752 **Isom LL, Scheuer T, Brownstein AB, Ragsdale DS, Murphy BJ, Catterall WA.** Functional co-
753 expression of the beta 1 and type IIA alpha subunits of sodium channels in a mammalian cell line. *J Biol*
754 *Chem* 270: 3306–12, 1995.

755 **Kaplan SA, Te AE, Blaivas JG.** Urodynamic findings in patients with diabetic cystopathy [Online]. *J*
756 *Urol* 153: 342–344, 1995. <http://www.ncbi.nlm.nih.gov/pubmed/7815578>.

757 **Kebapci N, Yenilmez A, Efe B, Entok E, Demirustu C.** Bladder dysfunction in type 2 diabetic patients.
758 *Neurourol Urodyn* 26: 814–819, 2007.

759 **Lee J-H, Kim E-G, Park B-G, Kim K-H, Cha S-K, Kong ID, Lee J-W, Jeong S-W.** Identification of
760 T-Type $\alpha 1H$ Ca^{2+} Channels ($Ca_v 3.2$) in Major Pelvic Ganglion Neurons. *J Neurophysiol* 87: 2844–2850,
761 2002.

762 **Liu PW, Bean BP.** Kv2 channel regulation of action potential repolarization and firing patterns in
763 superior cervical ganglion neurons and hippocampal CA1 pyramidal neurons. *J Neurosci* 34: 4991–5002,
764 2014.

765 **Liu Y, Sebastian B, Liu B, Zhang Y, Fissel JA, Pan B, Polydefkis M, Farah MH.** Sensory and
766 autonomic function and structure in footpads of a diabetic mouse model. *Sci Rep* 7: 41401, 2017.

767 **Malin SA, Nerbonne JM.** Molecular heterogeneity of the voltage-gated fast transient outward K⁺
768 current, I(Af), in mammalian neurons [Online]. *J Neurosci* 21: 8004–8014, 2001.
769 <http://www.ncbi.nlm.nih.gov/pubmed/11588173>.

770 **Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, Drash AL, Becker DJ,**
771 **Kuller LH, Greene DA, et al.** Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh
772 Epidemiology of Diabetes Complications Study [Online]. *Diabetes* 38: 1456–1461, 1989.
773 <http://www.ncbi.nlm.nih.gov/pubmed/2620781>.

774 **Mattingly GE, Fischer VW.** Peripheral neuropathy following prolonged exposure to streptozotocin-
775 induced diabetes in rats: a teased nerve fiber study [Online]. *Acta Neuropathol* 59: 133–138, 1983.
776 <http://www.ncbi.nlm.nih.gov/pubmed/6301203>.

777 **Medici F, Hawa M, Ianari A, Pyke DA, Leslie RD.** Concordance rate for type II diabetes mellitus in
778 monozygotic twins: actuarial analysis. *Diabetologia* 42: 146–150, 1999.

779 **Metz AE, Jarsky T, Martina M, Spruston N.** R-Type Calcium Channels Contribute to
780 Afterdepolarization and Bursting in Hippocampal CA1 Pyramidal Neurons [Online]. *J Neurosci* 25, 2005.
781 <http://www.jneurosci.org/content/25/24/5763/tab-figures-data> [25 Jun. 2018].

782 **Nadelhaft I, Vera PL.** Reduced urinary bladder afferent conduction velocities in streptozocin diabetic

783 rats [Online]. *Neurosci Lett* 135: 276–278, 1992. <http://www.ncbi.nlm.nih.gov/pubmed/1625809>.

784 **Naundorf B, Wolf F, Volgushev M.** Unique features of action potential initiation in cortical neurons.
785 *Nature* 440: 1060–1063, 2006.

786 **Perez-Reyes E.** Molecular Physiology of Low-Voltage-Activated T-type Calcium Channels. *Physiol Rev*
787 83: 117–161, 2003.

788 **Platkiewicz J, Brette R.** A threshold equation for action potential initiation. *PLoS Comput Biol* 6:
789 e1000850, 2010.

790 **Platkiewicz J, Brette R.** Impact of fast sodium channel inactivation on spike threshold dynamics and
791 synaptic integration. *PLoS Comput Biol* 7: e1001129, 2011.

792 **Rudy B, McBain CJ.** Kv3 channels: voltage-gated K⁺ channels designed for high-frequency repetitive
793 firing [Online]. *Trends Neurosci* 24: 517–526, 2001. <http://www.ncbi.nlm.nih.gov/pubmed/11506885>.

794 **Sasaki K, Chancellor MB, Goins WF, Phelan MW, Glorioso JC, de Groat WC, Yoshimura N.** Gene
795 therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat
796 model of diabetic cystopathy [Online]. *Diabetes* 53: 2723–2730, 2004.
797 <http://www.ncbi.nlm.nih.gov/pubmed/15448108>.

798 **Sasaki K, Chancellor MB, Phelan MW, Yokoyama T, Fraser MO, Seki S, Kubo K, Kumon H,**
799 **Groat WC, Yoshimura N.** Diabetic cystopathy correlates with a long-term decrease in nerve growth
800 factor levels in the bladder and lumbosacral dorsal root Ganglia. *J Urol* 168: 1259–1264, 2002.

801 **Springer MG, Kullmann PH, Horn JP.** Virtual leak channels modulate firing dynamics and synaptic
802 integration in rat sympathetic neurons: implications for ganglionic transmission in vivo. *J Physiol* 593:
803 803–823, 2015.

804 **Sullivan KA, Hayes JM, Wiggin TD, Backus C, Su Oh S, Lentz SI, Brosius 3rd F, Feldman EL.**
805 Mouse models of diabetic neuropathy. *Neurobiol Dis* 28: 276–285, 2007.

806 **Suzuki S, Rogawski MA.** T-type calcium channels mediate the transition between tonic and phasic firing
807 in thalamic neurons [Online]. *Proc Natl Acad Sci U S A* 86: 7228–7232, 1989.
808 <http://www.ncbi.nlm.nih.gov/pubmed/2550936>.

809 **Tompkins JD, Vizzard MA, Parsons RL.** Synaptic transmission at parasympathetic neurons of the
810 major pelvic ganglion from normal and diabetic male mice. *J Neurophysiol* 109: 988–995, 2013.

811 **UKPDS.** Intensive blood-glucose control with sulphonylureas or insulin compared with conventional
812 treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective
813 Diabetes Study (UKPDS) Group [Online]. *Lancet* 352: 837–853, 1998.
814 <http://www.ncbi.nlm.nih.gov/pubmed/9742976>.

815 **United States. Department of Health and Human Services., Center for Disease Control., National**
816 **Center for Health Statistics (U.S.).** Health, United States, 2016□: with chartbook on Long-term Trends
817 in Health [Online]. Hyattsville, MD: National Center for Health Statistics.
818 <https://www.cdc.gov/nchs/data/hsr/hsr16.pdf>.

819 **Vacher H, Mohapatra DP, Trimmer JS.** Localization and Targeting of Voltage-Dependent Ion
820 Channels in Mammalian Central Neurons. *Physiol Rev* 88: 1407–1447, 2008.

821 **Vandesompele J, De Preter K, Pattyn I, Poppe B, Van Roy N, De Paepe A, Speleman R.** Accurate
822 normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control
823 genes. *Genome Biol* 3: research0034.1–0034.11, 2002.

824 **Vinik AI, Maser RE, Mitchell BD, Freeman R.** Diabetic autonomic neuropathy [Online]. *Diabetes*
825 *Care* 26: 1553–1579, 2003. <http://www.ncbi.nlm.nih.gov/pubmed/12716821>.

826 **Vinik AI, Maser RE, Ziegler D.** Autonomic imbalance: prophet of doom or scope for hope? *Diabet Med*
827 28: 643–651, 2011.

828 **Wang B, Chandrasekera PC, Pippin JJ.** Leptin- and leptin receptor-deficient rodent models: relevance
829 for human type 2 diabetes [Online]. *Curr Diabetes Rev* 10: 131–145, 2014.
830 <http://www.ncbi.nlm.nih.gov/pubmed/24809394>.

831 **Weiser M, Vega-Saenz de Miera E, Kentros C, Moreno H, Franzen L, Hillman D, Baker H, Rudy**
832 **B.** Differential expression of Shaw-related K⁺ channels in the rat central nervous system [Online]. *J*
833 *Neurosci* 14: 949–972, 1994. <http://www.ncbi.nlm.nih.gov/pubmed/8120636>.

834 **White WE, Hooper SL.** Contamination of current-clamp measurement of neuron capacitance by voltage-
835 dependent phenomena. *J Neurophysiol* 110: 257–268, 2013.

836 **Won YJ, Whang K, Kong ID, Park KS, Lee JW, Jeong SW.** Expression profiles of high voltage-
837 activated calcium channels in sympathetic and parasympathetic pelvic ganglion neurons innervating the
838 urogenital system. *J Pharmacol Exp Ther* 317: 1064–1071, 2006.

839 **Yuan Z, Tang Z, He C, Tang W.** Diabetic cystopathy: A review. *J Diabetes* 7: 442–447, 2015.

840

841

- 7. 10-90% rise slope (mv/ms)
- 8. 90-10% decay slope (mv/ms)
- 9. Maximum ascending slope 0.5 ms bin (mv/ms) (used in depolarizing only)
- 10. Maximum rise slope (ms; 0.02 ms bin)
- 11. Maximum decay slope (ms; 0.02 ms Bin)
- 12. Threshold (mV; 0.25 ms before half max slope)
- 13. AHP area (mV·ms)
- 14. AHP decay tau (ms)

A**Weight** **B****Fasting Blood Glucose** **C****Fasting Serum Insulin**

A

Resting Membrane
Potential, $p = 0.365$

B

R_{in} , $p = 0.005$

C

τ , $p = 0.033$

D

Capacitance, $p < 0.001$

A Spike Slope Ascending (depolarizing), $p < 0.001$

B Half-Width, $p < 0.001$

C Max Rise Slope (rebound), $p = 0.059$

D Max Decay Slope (Rebound), $p = 0.016$

bioRxiv preprint doi: <https://doi.org/10.1101/360826>; this version posted July 6, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

E 10-90% Rise Time, $p = 0.039$

F 90-10% Decay time, $p < 0.001$

G 10-90% Rise Slope, $p = 0.360$

H 90-10% Decay slope, $p < 0.001$

I AP Area, $p = 0.002$

J AHP Area, $p = 0.767$

K AHP Amplitude, $p = 0.235$

L AHP Tau, $p = 0.003$

Calcium Channels

Sodium Channels

Potassium Channels

bioRxiv preprint doi: <https://doi.org/10.1101/360826>; this version posted July 6, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

A.

B.

A.

B.